Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Whitehawk Therapeutics (WHWK) Return on Equity: 2019-2025

Historic Return on Equity for Whitehawk Therapeutics (WHWK) over the last 6 years, with Sep 2025 value amounting to -0.63%.

  • Whitehawk Therapeutics' Return on Equity rose 21.00% to -0.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.63%, marking a year-over-year increase of 21.00%. This contributed to the annual value of -0.81% for FY2024, which is 31.00% down from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Return on Equity of -0.63% as of Q3 2025, which was down 25.89% from -0.50% recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Return on Equity registered a high of -0.05% during Q2 2021, and its lowest value of -1.16% during Q2 2022.
  • For the 3-year period, Whitehawk Therapeutics' Return on Equity averaged around -0.62%, with its median value being -0.56% (2023).
  • As far as peak fluctuations go, Whitehawk Therapeutics' Return on Equity slumped by 111bps in 2022, and later skyrocketed by 73bps in 2023.
  • Over the past 5 years, Whitehawk Therapeutics' Return on Equity (Quarterly) stood at -0.77% in 2021, then soared by 40bps to -0.37% in 2022, then fell by 19bps to -0.56% in 2023, then plummeted by 49bps to -1.05% in 2024, then rose by 21bps to -0.63% in 2025.
  • Its Return on Equity was -0.63% in Q3 2025, compared to -0.50% in Q2 2025 and -0.44% in Q1 2025.